PVR and acute myeloid leukemia: For the first time, we show that blocking the TIGIT-PVR/PVRL2 axis augments T-cell mediated lysis of AML cells and additionally enhances the cytotoxic effects of the CD33/CD3 BiTE® antibody construct AMG 330.